Akebia Therapeutics (AKBA) Stock Price, Quote & News

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phospho...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 871 2098

Fax: 617 871 2099

Website: www.akebia.com

Address:

245 First Street, Suite 1400, Cambridge, United States

PharmaExpert Jun. 25 at 12:35 PM

$AKBA will be an awsome wednesday! 🔥🔥🔥🔥

0 · Reply

Jeko44 Jun. 25 at 12:33 PM

$AKBA ok, out of the bullish pennant and should be on the way up now over the next two weeks, barring any unforeseen events. Ready for $5… Cowish

0 · Reply

Love_To_Learn Jun. 25 at 12:32 PM

$AKBA making the preparations let us proceed JOHN

0 · Reply

jdkd4 Jun. 25 at 12:17 PM

$AKBA Holding 13.3K shares $ALT and 26K shares $AKBA. It's fun watching them race against each other. Which one will explode first or will they do it together? One day, next week, next month, next year?? When they do, that will top off my retirement portfolio. I'll still work, but know i'll be secure. It's a gamble sure, but I only swing trade with funds I can afford to lose. And the true art of making money in investing is knowing when to sell and take my gains. Good luck everyone!!!

0 · Reply

Neo_Oracle Jun. 25 at 12:16 PM

$AKBA NEWS. THE TREND IS OUR FRIEND. NO PROMISES BUT NEO IS THINKING THAT AKBA CONTINUES THE UPWARD TREND THROUGH 2025, 2026, 2027 … GOOD LUCK 🍀 TO ALL OF US.

0 · Reply

Vulnerable Jun. 25 at 12:14 PM

$AKBA $PSTV yes long over due news for a biotech likely to come out soon...i need to visit my psychic today for some more revelations.

1 · Reply

Chamberlain12 Jun. 25 at 12:06 PM

$AKBA NEWS???NDDtrial? JB 3 months on summer vacation???

1 · Reply

ViperV22 Jun. 25 at 12:03 PM

$AKBA

0 · Reply

Love_To_Learn Jun. 25 at 11:59 AM

$AKBA so u see to those who laugh @ me just know that I LOVE KNOWIGNG U LAUGH NOW COMMENCING ON THE 3.67 MESSAGES AS I HAVE NO TIME FOR SUCH SILLY THINGS N PEOPLE

2 · Reply

Love_To_Learn Jun. 25 at 11:52 AM

$PSTV $AKBA so tell me not just on u 2 but every stock how is it that .................................... now mr and mrs pumpers u r all welcome to come and claim that u made this call or have this shirt LOL

2 · Reply

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

Jun 2, 2025, 4:05 PM EDT - 22 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2025, 8:00 AM EDT - 4 weeks ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025, 8:00 AM EDT - 4 weeks ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 13, 2025, 8:00 AM EDT - 6 weeks ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 12:44 PM EDT - 6 weeks ago

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 6 weeks ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 4:15 PM EDT - 7 weeks ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025, 8:00 AM EDT - 7 weeks ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Apr 3, 2025, 8:00 AM EDT - 2 months ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Mar 25, 2025, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 20, 2025, 8:18 AM EDT - 3 months ago

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MCHP

Mar 19, 2025, 10:17 PM EDT - 3 months ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 3 months ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 13, 2025, 10:21 AM EDT - 3 months ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 3 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 6, 2025, 8:00 AM EST - 3 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Feb 10, 2025, 5:43 AM EST - 4 months ago

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Jan 13, 2025, 8:00 AM EST - 5 months ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Dec 18, 2024, 8:00 AM EST - 6 months ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 7:00 AM EST - 7 months ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Nov 25, 2024, 8:00 AM EST - 7 months ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 20, 2024, 3:31 PM EST - 7 months ago

Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 14, 2024, 8:00 AM EST - 7 months ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Nov 12, 2024, 8:00 AM EST - 8 months ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 1:59 PM EST - 8 months ago

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 8 months ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 1, 2024, 8:00 AM EDT - 8 months ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

Oct 22, 2024, 8:00 AM EDT - 8 months ago

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Oct 15, 2024, 8:00 AM EDT - 9 months ago

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

Oct 10, 2024, 8:00 AM EDT - 9 months ago

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Oct 7, 2024, 8:00 AM EDT - 9 months ago

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Sep 5, 2024, 8:00 AM EDT - 10 months ago

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Aug 26, 2024, 8:00 AM EDT - 10 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Aug 10, 2024, 1:00 AM EDT - 11 months ago

Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 11 months ago

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 2, 2024, 8:00 AM EDT - 11 months ago

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Jul 11, 2024, 6:00 AM EDT - 1 year ago

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Jun 27, 2024, 8:18 AM EDT - 1 year ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Jun 24, 2024, 8:58 AM EDT - 1 year ago

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

May 23, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

May 9, 2024, 10:54 AM EDT - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 2, 2024, 8:30 AM EDT - 1 year ago

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

Apr 4, 2024, 5:56 PM EDT - 1 year ago

Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management

Mar 27, 2024, 8:45 PM EDT - 1 year ago

U.S. FDA approves Akebia's anemia drug

Mar 27, 2024, 8:26 PM EDT - 1 year ago

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Mar 14, 2024, 4:15 PM EDT - 1 year ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Mar 11, 2024, 5:05 PM EDT - 1 year ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

PharmaExpert Jun. 25 at 12:35 PM

$AKBA will be an awsome wednesday! 🔥🔥🔥🔥

0 · Reply

Jeko44 Jun. 25 at 12:33 PM

$AKBA ok, out of the bullish pennant and should be on the way up now over the next two weeks, barring any unforeseen events. Ready for $5… Cowish

0 · Reply

Love_To_Learn Jun. 25 at 12:32 PM

$AKBA making the preparations let us proceed JOHN

0 · Reply

jdkd4 Jun. 25 at 12:17 PM

0 · Reply

Neo_Oracle Jun. 25 at 12:16 PM

$AKBA NEWS. THE TREND IS OUR FRIEND. NO PROMISES BUT NEO IS THINKING THAT AKBA CONTINUES THE UPWARD TREND THROUGH 2025, 2026, 2027 … GOOD LUCK 🍀 TO ALL OF US.

0 · Reply

Vulnerable Jun. 25 at 12:14 PM

$AKBA $PSTV yes long over due news for a biotech likely to come out soon...i need to visit my psychic today for some more revelations.

1 · Reply

Chamberlain12 Jun. 25 at 12:06 PM

$AKBA NEWS???NDDtrial? JB 3 months on summer vacation???

1 · Reply

ViperV22 Jun. 25 at 12:03 PM

$AKBA

0 · Reply

Love_To_Learn Jun. 25 at 11:59 AM

$AKBA so u see to those who laugh @ me just know that I LOVE KNOWIGNG U LAUGH NOW COMMENCING ON THE 3.67 MESSAGES AS I HAVE NO TIME FOR SUCH SILLY THINGS N PEOPLE

2 · Reply

Love_To_Learn Jun. 25 at 11:52 AM

2 · Reply

Thomasboy1 Jun. 25 at 11:43 AM

$AKBA Ok it’s stepping up after consolidation n a brief pull back. Let’s see that 4 dollar holla by Friday! It’s the next level of progression. SHORTY done FAFO he did. Can’t stop this! GL 🍀

0 · Reply

Love_To_Learn Jun. 25 at 11:42 AM

$AKBA $PSTV witness what is said ! PSTV!

2 · Reply

Proffee Jun. 25 at 11:41 AM

$AKBA

3 · Reply

Swiss_Scroogy_McDuck Jun. 25 at 11:31 AM

$AKBA the messages from Love_to_learn make absolutely no sense to me. Or do I have any cognitive issue? Or my English is not good enough - even though I have level C2 in English… Idk

2 · Reply

Neo_Oracle Jun. 25 at 11:22 AM

$AKBA ONE YEAR IS GREEN. I LIKE THE TREND.

1 · Reply

Neo_Oracle Jun. 25 at 11:21 AM

$AKBA YEAR TO DATE IS GREEN. I LIKE THE TREND.

0 · Reply

Neo_Oracle Jun. 25 at 11:19 AM

$AKBA SIX MONTH CHART IS GREEN. I LIKE THE TREND.

0 · Reply

Neo_Oracle Jun. 25 at 11:17 AM

$AKBA THREE MONTH CHART IS GREEN. I LIKE THE TREND.

0 · Reply

Neo_Oracle Jun. 25 at 11:15 AM

$AKBA ONE MONTH CHART IS GREEN. I LIKE THE TREND.

0 · Reply

Neo_Oracle Jun. 25 at 11:13 AM

$AKBA ONE WEEK CHART IS GREEN. I LIKE THE TREND.

0 · Reply

Neo_Oracle Jun. 25 at 11:10 AM

$AKBA ONE DAY CHART IS GREEN. I LIKE THE TREND.

2 · Reply

Z09 Jun. 25 at 11:10 AM

$PRZO Regains Nasdaq Compliance Under Minimum Bid Rule $CYBL $ILUS $AKBA $AMTX

0 · Reply

Market Cap	956.00M
Revenue (ttm)	160.18M
Net Income (ttm)	-69.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-43.33%
Debt to Equity Ratio	1.89

Volume	5,297,800
Avg Vol	5,108,198
Day's Range	N/A - N/A
Shares Out	262.64M
Stochastic %K	40%
Beta	0.84
Analysts	Strong Sell
Price Target	$7.40